| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
(4E)-SUN9221 targets both the α1-adrenergic receptor and the 5-HT2 (serotonin) receptor. It functions as a dual antagonist, blocking the activation of these receptors by their endogenous ligands. α1-adrenergic receptors are G protein-coupled receptors that mediate vasoconstriction and smooth muscle contraction in response to norepinephrine and epinephrine. 5-HT2 receptors are serotonin receptors that play roles in platelet aggregation, vasoconstriction, and neurotransmission. By antagonizing both receptors, (4E)-SUN9221 produces antihypertensive effects through vasodilation and inhibits platelet aggregation, making it a valuable tool for studying cardiovascular and hemostatic pathways.
|
|---|---|
| ln Vitro |
In human platelet-rich plasma (PRP), (4E)-SUN9221 potently suppresses platelet aggregation brought on by collagen, ADP, and epinephrine, with IC50 values of 10 nM, 35 nM, and 14 nM, respectively. Strong α1-adrenergic antagonist activity (pA2 = 8.89±0.21) and 5-HT2 antagonist activity (pA2 = 8.74±0.22) are shown by (4E)-SUN9221 [1].
(4E)-SUN9221 demonstrates potent in vitro activity as a dual antagonist of α1-adrenergic and 5-HT2 receptors. The compound's antagonist activity has been confirmed in receptor binding and functional assays. In vitro studies have demonstrated that (4E)-SUN9221 effectively blocks receptor activation and downstream signaling. The compound's antiplatelet aggregation activity has been shown in response to collagen, ADP, and epinephrine-induced platelet aggregation. These activities are consistent with its dual receptor antagonism profile. The compound's potency at both receptors makes it a valuable tool for studying the interplay between adrenergic and serotonergic signaling in cardiovascular and platelet function. |
| ln Vivo |
(4E)-SUN9221 (1, 3, 10 mg/kg, p.o.) lowers blood pressure in conscious, dose-dependent spontaneously hypertensive rats (SHR). In SHR, (4E)-SUN9221 (3 mg/kg) demonstrates antihypertensive action [1].
(4E)-SUN9221 exhibits antihypertensive activity in spontaneously hypertensive rats (SHR). When administered at 3 mg/kg, the compound demonstrates blood pressure-lowering effects. The antihypertensive activity is consistent with its dual antagonism of α1-adrenergic and 5-HT2 receptors, which mediate vasoconstriction. The compound's ability to lower blood pressure in hypertensive animal models supports its utility for studying cardiovascular pharmacology and the role of these receptors in hypertension. The compound's antiplatelet aggregation activity also suggests potential utility in studying thrombosis and hemostasis. Detailed in vivo efficacy data, including dose-response relationships and duration of action, are available in the primary literature. |
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cell-based) assay for (4E)-SUN9221 measures the binding affinity of the compound to α1-adrenergic and 5-HT2 receptors. Radioligand binding assays are performed using membrane preparations from cells expressing the recombinant human α1-adrenergic receptor or 5-HT2 receptor. Varying concentrations of (4E)-SUN9221 (typically ranging from nanomolar to micromolar) are incubated with the membrane preparation and a radiolabeled ligand specific for the receptor. The amount of bound radioligand is measured by scintillation counting, and the IC50 or Ki values are determined by fitting competition binding curves. The compound is dissolved in DMSO and diluted in assay buffer to achieve the desired final concentrations. Appropriate positive controls (known receptor antagonists) and negative controls are included in each assay run.
|
| Cell Assay |
The in vitro cellular assay for (4E)-SUN9221 is performed using cells expressing α1-adrenergic or 5-HT2 receptors, such as HEK293 cells stably or transiently transfected with the receptor of interest. Cells are cultured in appropriate medium and treated with varying concentrations of (4E)-SUN9221 or vehicle control (DMSO) prior to stimulation with receptor agonists (e.g., phenylephrine for α1-adrenergic or serotonin for 5-HT2). Receptor activation is measured by detecting downstream signaling events such as calcium mobilization (using fluorescent calcium indicators), inositol phosphate accumulation, or reporter gene activity. The antagonist activity of (4E)-SUN9221 is quantified by measuring the inhibition of agonist-induced signaling. Dose-response curves are generated to determine IC50 values. The compound's effects on platelet aggregation can also be assessed in platelet-rich plasma using aggregometry.
|
| Animal Protocol |
In vivo animal experiments with (4E)-SUN9221 are typically conducted using spontaneously hypertensive rats (SHR) or other hypertensive animal models. Animals are instrumented for blood pressure measurement via telemetry or tail-cuff plethysmography. (4E)-SUN9221 is administered via oral gavage or intravenous injection at various doses (e.g., 3 mg/kg). Blood pressure and heart rate are measured at baseline and at specified time points after compound administration. For antiplatelet aggregation studies, blood samples are collected and platelet aggregation is induced by agonists such as collagen, ADP, or epinephrine, and aggregation is measured using aggregometry. The antihypertensive and antiplatelet effects are quantified and compared to vehicle-treated controls.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic (PK) parameters for (4E)-SUN9221 are not extensively documented in publicly available sources. As a small-molecule antagonist with a molecular weight of approximately 454.55, the compound is expected to have reasonable oral bioavailability. The compound has a chemical formula of C25H31FN4O3. For in vivo administration, (4E)-SUN9221 is typically formulated using appropriate vehicles to ensure adequate solubility and stability. The compound should be stored under conditions recommended by the manufacturer to maintain stability and prevent degradation. Detailed PK parameters including half-life, clearance, volume of distribution, and maximum concentration (Cmax) are available in the primary literature and should be consulted for specific experimental planning.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for (4E)-SUN9221 are not extensively documented in publicly available sources. As a research-grade compound, (4E)-SUN9221 is intended for laboratory research purposes only and is not approved for human therapeutic use. Standard laboratory safety practices should be followed when handling this compound, including the use of appropriate personal protective equipment and working in a well-ventilated area. In animal studies, (4E)-SUN9221 has been administered at doses effective for antihypertensive activity without reports of overt toxicity. However, comprehensive toxicological profiling (e.g., LD50, maximum tolerated dose, organ-specific toxicity) is not available from the current search results and would require consultation of the primary literature or safety data sheets.
|
| References |
[1]. Mizuno A, et al. Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):246-56.
|
| Additional Infomation |
(4E)-SUN9221 is a research compound developed for studying the role of α1-adrenergic and 5-HT2 receptors in cardiovascular function and platelet aggregation. The compound exhibits potent dual antagonist activity against both receptors and demonstrates antihypertensive and antiplatelet aggregation effects. (4E)-SUN9221 has been shown to lower blood pressure in spontaneously hypertensive rats and inhibit platelet aggregation induced by various agonists. The compound is not currently in clinical trials nor approved for therapeutic use; it remains an investigational tool compound for preclinical cardiovascular research. (4E)-SUN9221 is available from various chemical suppliers for research purposes. Its utility lies in its ability to simultaneously block both adrenergic and serotonergic signaling pathways.
|
| Molecular Formula |
C25H31FN4O3
|
|---|---|
| Molecular Weight |
454.5370
|
| Exact Mass |
454.238
|
| CAS # |
222318-55-0
|
| PubChem CID |
9911796
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
716
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1CC/C(=N\O)/C2=C(C1=O)N(C=C2)CCCCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F
|
| InChi Key |
NJODDWBWSIFQMT-HPNDGRJYSA-N
|
| InChi Code |
InChI=1S/C25H31FN4O3/c1-28-14-11-22(27-33)21-10-17-30(23(21)25(28)32)13-3-2-12-29-15-8-19(9-16-29)24(31)18-4-6-20(26)7-5-18/h4-7,10,17,19,33H,2-3,8-9,11-16H2,1H3/b27-22+
|
| Chemical Name |
(4E)-1-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-4-hydroxyimino-7-methyl-5,6-dihydropyrrolo[2,3-c]azepin-8-one
|
| Synonyms |
(4E)-SUN9221; (4E) SUN9221; (4E)-SUN-9221; (4E)-SUN 9221; (4E) SUN 9221
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2000 mL | 11.0001 mL | 22.0003 mL | |
| 5 mM | 0.4400 mL | 2.2000 mL | 4.4001 mL | |
| 10 mM | 0.2200 mL | 1.1000 mL | 2.2000 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA